This is a Validated Antibody Database (VAD) review about mouse Gzmb, based on 123 published articles (read how Labome selects the articles), using Gzmb antibody in all methods. It is aimed to help Labome visitors find the most suited Gzmb antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Gzmb synonym: AI553453; CCP-1/C11; CCP1; Ctla-1; Ctla1; GZB

BioLegend
mouse recombinant (QA16A02)
  • flow cytometry; mouse; 1:25; loading ...
BioLegend Gzmb antibody (Biolegend, 372206) was used in flow cytometry on mouse samples at 1:25. Nat Commun (2022) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig 6d, s4a
BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on mouse samples (fig 6d, s4a). Front Cell Infect Microbiol (2022) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; 1:50; loading ...; fig 6h
BioLegend Gzmb antibody (Biolgend, 372206) was used in flow cytometry on mouse samples at 1:50 (fig 6h). Nat Commun (2022) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; fig 3f
BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on mouse samples (fig 3f). Theranostics (2022) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig s1a, s4f
BioLegend Gzmb antibody (BioLegend, 515408) was used in flow cytometry on mouse samples (fig s1a, s4f). Sci Adv (2022) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig 3f
BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on mouse samples (fig 3f). Oncoimmunology (2022) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; fig s6d
BioLegend Gzmb antibody (Biolegend, QA16A02) was used in flow cytometry on mouse samples (fig s6d). Nat Commun (2022) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; 1:50; loading ...; fig 6i, s8
BioLegend Gzmb antibody (Biolegend, 372213) was used in flow cytometry on mouse samples at 1:50 (fig 6i, s8). Nat Commun (2022) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; fig 2m
BioLegend Gzmb antibody (Biolegend, 515403) was used in flow cytometry on mouse samples (fig 2m). J Immunother Cancer (2022) ncbi
rat recombinant (QA18A28)
  • flow cytometry; mouse; loading ...; fig 1e, s2e
BioLegend Gzmb antibody (BioLegend, 396412) was used in flow cytometry on mouse samples (fig 1e, s2e). J Immunother Cancer (2022) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; 1:50; fig 4c
BioLegend Gzmb antibody (BioLegend, 515403) was used in flow cytometry on mouse samples at 1:50 (fig 4c). J Biol Chem (2022) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; fig s10
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on human samples (fig s10). Oncoimmunology (2022) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; 1:100; fig 4f, 4g
BioLegend Gzmb antibody (Biolegend, 372203) was used in flow cytometry on mouse samples at 1:100 (fig 4f, 4g). Nat Nanotechnol (2022) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; 1:100; fig 3f, 3g, s7c
BioLegend Gzmb antibody (Biolegend, 515408) was used in flow cytometry on mouse samples at 1:100 (fig 3f, 3g, s7c). Nat Nanotechnol (2022) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; 1:100; fig 1d
BioLegend Gzmb antibody (BioLegend, QA16A02) was used in flow cytometry on mouse samples at 1:100 (fig 1d). J Immunother Cancer (2021) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig 5b
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on mouse samples (fig 5b). Commun Biol (2021) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig s4c
BioLegend Gzmb antibody (Biolegend, 515408) was used in flow cytometry on mouse samples (fig s4c). J Immunother Cancer (2021) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; loading ...; fig s3b
BioLegend Gzmb antibody (Biolegend, 372213) was used in flow cytometry on mouse samples (fig s3b). J Immunother Cancer (2021) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; 1:100; loading ...; fig s4b
BioLegend Gzmb antibody (BioLegend, 515405) was used in flow cytometry on mouse samples at 1:100 (fig s4b). iScience (2021) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; 1:100; fig 4e
BioLegend Gzmb antibody (BioLegend, 372204) was used in flow cytometry on mouse samples at 1:100 (fig 4e). Nat Commun (2021) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; loading ...; fig s4c
BioLegend Gzmb antibody (Biolegend, 372208) was used in flow cytometry on mouse samples (fig s4c). JCI Insight (2021) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; 1:200; loading ...; fig 3d
BioLegend Gzmb antibody (BioLegend, 515405) was used in flow cytometry on mouse samples at 1:200 (fig 3d). Proc Natl Acad Sci U S A (2021) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; 1:50; fig s16a
BioLegend Gzmb antibody (BioLegend, QA16A02) was used in flow cytometry on mouse samples at 1:50 (fig s16a). Sci Transl Med (2021) ncbi
rat recombinant (QA18A28)
  • flow cytometry; mouse; loading ...; fig 8a
BioLegend Gzmb antibody (BioLegend, 396413) was used in flow cytometry on mouse samples (fig 8a). Neoplasia (2021) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; human; fig 2f
  • flow cytometry; mouse; fig 6f
BioLegend Gzmb antibody (Biolegend, 372204) was used in flow cytometry on human samples (fig 2f) and in flow cytometry on mouse samples (fig 6f). Sci Rep (2021) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; human; loading ...; fig 7e
BioLegend Gzmb antibody (Biolegend, 372221) was used in flow cytometry on human samples (fig 7e). Am J Respir Crit Care Med (2021) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; loading ...; fig 3e
BioLegend Gzmb antibody (Biolegend, 515406) was used in flow cytometry on human samples (fig 3e). Cell (2020) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; 1:100; loading ...; fig ev2c
BioLegend Gzmb antibody (BioLegend, 515408) was used in flow cytometry on mouse samples at 1:100 (fig ev2c). EMBO Mol Med (2020) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig 5f, 5g
BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on mouse samples (fig 5f, 5g). Science (2020) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; 1:100; loading ...; fig 8d
BioLegend Gzmb antibody (BioLegend, 515406) was used in flow cytometry on mouse samples at 1:100 (fig 8d). Nat Commun (2020) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; fig 3h
BioLegend Gzmb antibody (Biolegend, QA16A02) was used in flow cytometry on mouse samples (fig 3h). Nature (2019) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig 2d, 2l
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on mouse samples (fig 2d, 2l). Science (2019) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig s5a
BioLegend Gzmb antibody (Biolegend, 515407) was used in flow cytometry on mouse samples (fig s5a). Cell (2019) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; loading ...; fig 10b
BioLegend Gzmb antibody (Biolegend, 515403) was used in flow cytometry on human samples (fig 10b). Cell Mol Gastroenterol Hepatol (2020) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; loading ...; fig 5c
BioLegend Gzmb antibody (Biolegend, 372208) was used in flow cytometry on mouse samples (fig 5c). Cell (2019) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; 1:50; fig 4c, 6j
BioLegend Gzmb antibody (Biolegend, 515403) was used in flow cytometry on mouse samples at 1:50 (fig 4c, 6j). Nat Commun (2019) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; loading ...; fig 3a
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on human samples (fig 3a). J Immunol (2019) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; loading ...; fig 2a
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on human samples (fig 2a). J Immunol (2019) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; 1:100; loading ...; fig s2b
BioLegend Gzmb antibody (Biolegend, 515403) was used in flow cytometry on mouse samples at 1:100 (fig s2b). Nat Commun (2019) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; 1:100; loading ...; fig 3h
BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on human samples at 1:100 (fig 3h). elife (2019) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig 3a
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on mouse samples (fig 3a). Front Immunol (2018) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; loading ...; fig s1d
BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on human samples (fig s1d). Proc Natl Acad Sci U S A (2018) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig 3f
BioLegend Gzmb antibody (Biolegend, 515403) was used in flow cytometry on mouse samples (fig 3f). Cell Rep (2018) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; loading ...; fig 3m
BioLegend Gzmb antibody (Biolegend, 372204) was used in flow cytometry on mouse samples (fig 3m). Cancer Res (2018) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; loading ...; fig s6a
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on human samples (fig s6a). Sci Immunol (2018) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; mouse; loading ...; fig 5c
BioLegend Gzmb antibody (BioLegend, QA16A02) was used in flow cytometry on mouse samples (fig 5c). Cell Immunol (2018) ncbi
mouse recombinant (QA16A02)
  • flow cytometry; human; loading ...; fig 6c
BioLegend Gzmb antibody (BioLegend, QA16A02) was used in flow cytometry on human samples (fig 6c). Int J Infect Dis (2018) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; fig s2b
BioLegend Gzmb antibody (BioLegend, 515408) was used in flow cytometry on mouse samples (fig s2b). Cell (2018) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig s10g
BioLegend Gzmb antibody (BioLegend, 515403) was used in flow cytometry on mouse samples (fig s10g). Nature (2018) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; 1:200; loading ...; fig 8b
BioLegend Gzmb antibody (Biolegend, 515403) was used in flow cytometry on mouse samples at 1:200 (fig 8b). Nat Cell Biol (2017) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...
In order to evaluate mouse models of hepacivirus infection, BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on mouse samples . Science (2017) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; loading ...; fig 4c
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on human samples (fig 4c). Oncotarget (2017) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; loading ...; fig 6a
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on human samples (fig 6a). J Exp Med (2017) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; loading ...; fig s6d
In order to demonstrate that neonatal CD8 positive T cells have a specific genetic program biased toward the innate immune response, BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on human samples (fig s6d). Cell Rep (2016) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; loading ...; fig 4a
In order to functionally characterize herpes simplex virus-specific CD8 positive T cells, BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on human samples (fig 4a). J Virol (2017) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; fig 1e
In order to investigate the role of Eomes in the retention of liver natural killer cells, BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on human samples (fig 1e). J Immunol (2016) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; 1:400; loading ...; fig 3a
In order to test how inhibiting autophagy impacts antitumor immune responses in immune-competent mouse models of melanoma and mammary cancer, BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on mouse samples at 1:400 (fig 3a). J Clin Invest (2016) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; loading ...; fig 3b
In order to study T cell migration in inflammatory demyelinating lesions confined to optic nerves and spinal cord, BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on mouse samples (fig 3b). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; fig 5
BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on human samples (fig 5). PLoS Pathog (2016) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; 1:200; loading ...; tbl s2
In order to identify and characterize follicular cytotoxic T cells, BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on mouse samples at 1:200 (tbl s2). Nat Immunol (2016) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; fig 1
BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on human samples (fig 1). J Immunol (2016) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; loading ...; fig s1
In order to characterize innate lymphoid cell subpopulations isolated from patients with systemic sclerosis, BioLegend Gzmb antibody (biolegend, GB11) was used in flow cytometry on human samples (fig s1). J Immunol (2016) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; fig 1
In order to assess arming of MAIT cell cytolytic antimicrobial activity and induction by IL-7 and faulty in HIV-1 infection, BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on human samples (fig 1). PLoS Pathog (2015) ncbi
mouse monoclonal (GB11)
  • immunocytochemistry; human; fig 2
In order to investigate the role of VAMP8 in exocytosis, BioLegend Gzmb antibody (BioLegend, GB11) was used in immunocytochemistry on human samples (fig 2). J Cell Biol (2015) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; fig 1
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on mouse samples (fig 1). J Immunol (2015) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse
In order to report that AMPK regulates protein phosphatase activity to control the of survival and function of CD8+ T cells, thus regulating immune surveillance of tumors, BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on mouse samples . Oncotarget (2015) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; fig 7
  • flow cytometry; human; fig 4
BioLegend Gzmb antibody (Biolegend, GB11) was used in flow cytometry on mouse samples (fig 7) and in flow cytometry on human samples (fig 4). J Immunol (2015) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; fig 4
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on human samples (fig 4). J Virol (2015) ncbi
mouse monoclonal (GB11)
  • flow cytometry; human; 5,000 ug/ml; fig 3
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on human samples at 5,000 ug/ml (fig 3). J Surg Res (2015) ncbi
mouse monoclonal (GB11)
  • flow cytometry; mouse; fig 6
BioLegend Gzmb antibody (BioLegend, GB11) was used in flow cytometry on mouse samples (fig 6). Am J Pathol (2014) ncbi
mouse monoclonal (GB11)
BioLegend Gzmb antibody (BioLegend, 515403) was used . Cancer Res (2014) ncbi
Invitrogen
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 5e
Invitrogen Gzmb antibody (eBioScience, 12-8898-82) was used in flow cytometry on mouse samples (fig 5e). J Immunother Cancer (2022) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig s9f
Invitrogen Gzmb antibody (eBioscience, 17-8898-82) was used in flow cytometry on mouse samples (fig s9f). J Clin Invest (2022) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; fig 3b
Invitrogen Gzmb antibody (eBioscience, 12-8898-80) was used in flow cytometry on mouse samples (fig 3b). Theranostics (2021) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; 1:200; fig 6e
Invitrogen Gzmb antibody (eBioscience, 25-8898-82) was used in flow cytometry on mouse samples at 1:200 (fig 6e). J Immunother Cancer (2021) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; 1:100; loading ...; fig s8d
Invitrogen Gzmb antibody (Thermo Fisher Scientific, 48-8898-80) was used in flow cytometry on mouse samples at 1:100 (fig s8d). Nat Commun (2021) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; fig 1c
Invitrogen Gzmb antibody (eBioscience, NGZB) was used in flow cytometry on mouse samples (fig 1c). JCI Insight (2021) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 6h
Invitrogen Gzmb antibody (eBioscience, 12-8898-80) was used in flow cytometry on mouse samples (fig 6h). Signal Transduct Target Ther (2021) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; fig 13j
Invitrogen Gzmb antibody (eBioscience, 12-8898-80) was used in flow cytometry on mouse samples (fig 13j). Cell Mol Gastroenterol Hepatol (2021) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig s2d
Invitrogen Gzmb antibody (eBioscience, 25-8898-82) was used in flow cytometry on mouse samples (fig s2d). Proc Natl Acad Sci U S A (2020) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; 1:200; loading ...; fig 3s4e
Invitrogen Gzmb antibody (Thermo Fisher Scientific, 17-8898-82) was used in flow cytometry on mouse samples at 1:200 (fig 3s4e). elife (2020) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 4j
Invitrogen Gzmb antibody (eBioscience, 25-8898-80) was used in flow cytometry on mouse samples (fig 4j). Cell Rep (2020) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; 1:200; loading ...; fig 5c
Invitrogen Gzmb antibody (eBioscience, 11889882) was used in flow cytometry on mouse samples at 1:200 (fig 5c). Nat Commun (2019) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 5f
Invitrogen Gzmb antibody (eBioscience, 12-8898-80) was used in flow cytometry on mouse samples (fig 5f). Cell (2019) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; 1:100; loading ...; fig s1a
Invitrogen Gzmb antibody (eBioscience, 12-4321) was used in flow cytometry on mouse samples at 1:100 (fig s1a). Cell (2019) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 2f
Invitrogen Gzmb antibody (eBioscience, NGZB) was used in flow cytometry on mouse samples (fig 2f). Immune Netw (2018) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 3e
Invitrogen Gzmb antibody (eBioscience, 12-8898) was used in flow cytometry on mouse samples (fig 3e). Oncoimmunology (2018) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; 1:66; loading ...; fig 2d
Invitrogen Gzmb antibody (eBioscience, 12-8898-82) was used in flow cytometry on mouse samples at 1:66 (fig 2d). Nat Commun (2018) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 1g
Invitrogen Gzmb antibody (eBioscience, 12-8898-80) was used in flow cytometry on mouse samples (fig 1g). Nat Commun (2018) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 6c
Invitrogen Gzmb antibody (eBioscience, NGZB) was used in flow cytometry on mouse samples (fig 6c). Nat Commun (2018) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 4a
Invitrogen Gzmb antibody (Thermo Fisher, NGZB) was used in flow cytometry on mouse samples (fig 4a). Oncogene (2018) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; fig 3b
Invitrogen Gzmb antibody (eBiosciences, 11-8898-82) was used in flow cytometry on mouse samples (fig 3b). Cell (2018) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 3f
Invitrogen Gzmb antibody (Thermo Fisher, NGZB) was used in flow cytometry on mouse samples (fig 3f). Science (2018) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 3c
In order to investigate the role of Egr2 and 3 in adaptive immune responses and its mechanism, Invitrogen Gzmb antibody (eBiosciences, 12-8898-80) was used in flow cytometry on mouse samples (fig 3c). J Exp Med (2017) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 4k
In order to study the role of MYSM1 in T cell development, Invitrogen Gzmb antibody (eBioscience, NGZB) was used in flow cytometry on mouse samples (fig 4k). Immunology (2017) ncbi
domestic rabbit polyclonal
  • immunocytochemistry; human; fig 3
  • western blot; human; fig 3
In order to investigate the functions of EZH2 in human T cells, Invitrogen Gzmb antibody (Thermo, PA5-17457) was used in immunocytochemistry on human samples (fig 3) and in western blot on human samples (fig 3). Cell Death Dis (2016) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; fig 3b
In order to study mTOR signaling in gamma delta T cells, Invitrogen Gzmb antibody (eBioscience, NGZB) was used in flow cytometry on mouse samples (fig 3b). J Leukoc Biol (2016) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; 1:100; fig s6a
In order to suggest that locally synthesized C1q promotes tumor growth, Invitrogen Gzmb antibody (eBioscience, NGZM) was used in flow cytometry on mouse samples at 1:100 (fig s6a). Nat Commun (2016) ncbi
rat monoclonal (16G6)
  • western blot; human; loading ...; fig 2c
Invitrogen Gzmb antibody (eBioscience, 16G6) was used in western blot on human samples (fig 2c). J Biol Chem (2016) ncbi
rat monoclonal (16G6)
  • flow cytometry; mouse
In order to study PI3Kdelta in CD8+ T cells during infection with Listeria monocytogenes, Invitrogen Gzmb antibody (eBioscience, 16G6) was used in flow cytometry on mouse samples . J Immunol (2015) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; 1:100; fig s5
Invitrogen Gzmb antibody (eBioscience, 50-8898) was used in flow cytometry on mouse samples at 1:100 (fig s5). Nat Commun (2015) ncbi
rat monoclonal (NGZB)
  • flow cytometry; mouse; loading ...; fig 5e
In order to assess the capacity of dried microneedle array vaccination on effector/memory CD8 positive T cell subsets, Invitrogen Gzmb antibody (eBioscience, NGZB) was used in flow cytometry on mouse samples (fig 5e). Vaccine (2015) ncbi
rat monoclonal (16G6)
  • flow cytometry; mouse
In order to report coreceptor gene imprinting as a critical determinant of lineage fate determination in the thymus, Invitrogen Gzmb antibody (eBioscience, 16G6) was used in flow cytometry on mouse samples . EMBO J (2012) ncbi
rat monoclonal (16G6)
  • flow cytometry; mouse; fig 2, 3
In order to report sex-dependent, B7-H1-dependent differences in tumor immunity, Invitrogen Gzmb antibody (eBioscience, 16G6) was used in flow cytometry on mouse samples (fig 2, 3). J Immunol (2010) ncbi
rat monoclonal (16G6)
  • flow cytometry; mouse; fig 2e
In order to assess the consequences of phosphoinositide (3,4,5)-triphosphate binding to 3-phosphoinositide-dependent kinase 1, Invitrogen Gzmb antibody (eBioscience, 16G6) was used in flow cytometry on mouse samples (fig 2e). Mol Cell Biol (2009) ncbi
rat monoclonal (16G6)
  • flow cytometry; mouse; fig 4
In order to study how multifactorial adjuvants show reduced toxicity and enhanced efficacy compared to unitary adjuvants as cancer vaccines, Invitrogen Gzmb antibody (eBioscience, 16G6) was used in flow cytometry on mouse samples (fig 4). Blood (2008) ncbi
rat monoclonal (16G6)
  • flow cytometry; mouse
Invitrogen Gzmb antibody (eBioscience, 16G6) was used in flow cytometry on mouse samples . Nat Immunol (2008) ncbi
Abcam
domestic rabbit polyclonal
  • immunohistochemistry; mouse; loading ...; fig 5g
Abcam Gzmb antibody (Abcam, ab4059) was used in immunohistochemistry on mouse samples (fig 5g). elife (2022) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 5g, s5b
Abcam Gzmb antibody (Abcam, 4059) was used in immunohistochemistry - paraffin section on mouse samples (fig 5g, s5b). J Immunother Cancer (2022) ncbi
domestic rabbit monoclonal (EPR22645-206)
  • western blot; human; loading ...; fig 2e
Abcam Gzmb antibody (Abcam, ab255598) was used in western blot on human samples (fig 2e). Mol Cancer (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:100; loading ...; fig 7f
Abcam Gzmb antibody (Abcam, ab4059) was used in immunohistochemistry - paraffin section on mouse samples at 1:100 (fig 7f). NPJ Breast Cancer (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry; mouse; 1:100; loading ...; fig 4c
Abcam Gzmb antibody (Abcam, ab4059) was used in immunohistochemistry on mouse samples at 1:100 (fig 4c). Am J Cancer Res (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:300; fig s2e
Abcam Gzmb antibody (Abcam, ab4059) was used in immunohistochemistry - paraffin section on mouse samples at 1:300 (fig s2e). Nat Commun (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 1h
Abcam Gzmb antibody (Abcam, ab4059) was used in immunohistochemistry - paraffin section on mouse samples (fig 1h). Adv Sci (Weinh) (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; 1:150; loading ...; fig 1c
  • immunohistochemistry - paraffin section; mouse; 1:150; loading ...; fig 3d
Abcam Gzmb antibody (Abcam, ab4059) was used in immunohistochemistry - paraffin section on human samples at 1:150 (fig 1c) and in immunohistochemistry - paraffin section on mouse samples at 1:150 (fig 3d). NPJ Aging Mech Dis (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 6e
Abcam Gzmb antibody (Abcam, AB4059) was used in immunohistochemistry - paraffin section on mouse samples (fig 6e). Cell (2020) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; loading ...; fig 1a
Abcam Gzmb antibody (Abcam, ab4059) was used in immunohistochemistry - paraffin section on human samples (fig 1a). Sci Rep (2018) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:300; fig 5e
Abcam Gzmb antibody (Abcam, ab4059) was used in immunohistochemistry - paraffin section on mouse samples at 1:300 (fig 5e). JCI Insight (2017) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:250; loading ...; fig 6a
Abcam Gzmb antibody (Abcam, ab4059) was used in immunohistochemistry - paraffin section on mouse samples at 1:250 (fig 6a). J Exp Med (2016) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 3c
In order to establish and characterize a mouse model of narcolepsy, Abcam Gzmb antibody (AbCam, ab4059) was used in immunohistochemistry - paraffin section on mouse samples (fig 3c). Proc Natl Acad Sci U S A (2016) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 6b
In order to investigate the effect of Tasquinimod in bladder cancer, Abcam Gzmb antibody (Abcam, ab4059) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 6b). Oncoimmunology (2016) ncbi
Cell Signaling Technology
domestic rabbit polyclonal
  • flow cytometry; mouse
Cell Signaling Technology Gzmb antibody (Cell Signaling Technology, 4275) was used in flow cytometry on mouse samples . EMBO Mol Med (2021) ncbi
domestic rabbit polyclonal
  • western blot; mouse; 1:2000; loading ...; fig 3d
Cell Signaling Technology Gzmb antibody (Cell Signaling Technology, 4275) was used in western blot on mouse samples at 1:2000 (fig 3d). Nat Commun (2019) ncbi
domestic rabbit polyclonal
  • other; human; loading ...; fig 4c
Cell Signaling Technology Gzmb antibody (Cell Signaling, 4275) was used in other on human samples (fig 4c). Cancer Cell (2018) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig s11a
In order to quantify changes in cytoplasmic and mitochondrial interactomes in response to apoptosis initiation as a function of caspase activity, Cell Signaling Technology Gzmb antibody (Cell Signaling, 4275) was used in western blot on human samples (fig s11a). Mol Syst Biol (2017) ncbi
Articles Reviewed
  1. Yang P, Qin H, Li Y, Xiao A, Zheng E, Zeng H, et al. CD36-mediated metabolic crosstalk between tumor cells and macrophages affects liver metastasis. Nat Commun. 2022;13:5782 pubmed publisher
  2. Hou X, Shi Y, Kang X, Rousu Z, Li D, Wang M, et al. Echinococcus granulosus: The establishment of the metacestode in the liver is associated with control of the CD4+ T-cell-mediated immune response in patients with cystic echinococcosis and a mouse model. Front Cell Infect Microbiol. 2022;12:983119 pubmed publisher
  3. Xie F, Zhou X, Su P, Li H, Tu Y, Du J, et al. Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling. Nat Commun. 2022;13:4461 pubmed publisher
  4. Wu B, Song M, Dong Q, Xiang G, Li J, Ma X, et al. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer. Theranostics. 2022;12:5086-5102 pubmed publisher
  5. Chambers A, Lupo K, Wang J, Cao J, Utturkar S, Lanman N, et al. Engineered natural killer cells impede the immunometabolic CD73-adenosine axis in solid tumors. elife. 2022;11: pubmed publisher
  6. Huang J, Wang X, Li B, Shen S, Wang R, Tao H, et al. L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression. J Immunother Cancer. 2022;10: pubmed publisher
  7. Garnier L, Pick R, Montorfani J, Sun M, Brighouse D, Liaudet N, et al. IFN-γ-dependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis. Sci Adv. 2022;8:eabl5162 pubmed publisher
  8. Pan C, Wu Q, Wang S, Mei Z, Zhang L, Gao X, et al. Combination with Toll-like receptor 4 (TLR4) agonist reverses GITR agonism mediated M2 polarization of macrophage in Hepatocellular carcinoma. Oncoimmunology. 2022;11:2073010 pubmed publisher
  9. Piao W, Li L, Saxena V, Iyyathurai J, Lakhan R, Zhang Y, et al. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. Nat Commun. 2022;13:2176 pubmed publisher
  10. Xiong W, Gao X, Zhang T, Jiang B, Hu M, Bu X, et al. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun. 2022;13:1700 pubmed publisher
  11. van Vloten J, Matuszewska K, Minow M, Minott J, Santry L, Pereira M, et al. Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. J Immunother Cancer. 2022;10: pubmed publisher
  12. Tang T, Huang X, Zhang G, Lu M, Hong Z, Wang M, et al. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis. J Immunother Cancer. 2022;10: pubmed publisher
  13. Cha J, Chan L, Wang Y, Chu Y, Wang C, Lee H, et al. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. J Biol Chem. 2022;298:101817 pubmed publisher
  14. Yang K, Han J, Asada M, Gill J, Park J, Sathe M, et al. Cytoplasmic RNA quality control failure engages mTORC1-mediated autoinflammatory disease. J Clin Invest. 2022;132: pubmed publisher
  15. Kono M, Komatsuda H, Yamaki H, Kumai T, Hayashi R, Wakisaka R, et al. Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. Oncoimmunology. 2022;11:2021619 pubmed publisher
  16. Liu Y, Wang L, Song Q, Ali M, Crowe W, Kucera G, et al. Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion. Nat Nanotechnol. 2022;17:206-216 pubmed publisher
  17. Liu H, Pedros C, Kong K, Canonigo Balancio A, Xue W, Altman A. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy. J Immunother Cancer. 2021;9: pubmed publisher
  18. Susukida T, Kuwahara S, Song B, Kazaoka A, Aoki S, Ito K. Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity. Commun Biol. 2021;4:1137 pubmed publisher
  19. Jiang Y, Yuan Y, Chen M, Li S, Bai J, Zhang Y, et al. PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression. Theranostics. 2021;11:9162-9176 pubmed publisher
  20. Liu Z, Wang T, She Y, Wu K, Gu S, Li L, et al. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol Cancer. 2021;20:105 pubmed publisher
  21. Lu C, Liu Z, Klement J, Yang D, Merting A, Poschel D, et al. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape. J Immunother Cancer. 2021;9: pubmed publisher
  22. Wu S, Xiao Y, Wei J, Xu X, Jin X, Hu X, et al. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer. J Immunother Cancer. 2021;9: pubmed publisher
  23. Tulotta C, Lefley D, Moore C, Amariutei A, Spicer Hadlington A, Quayle L, et al. IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. NPJ Breast Cancer. 2021;7:95 pubmed publisher
  24. Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, et al. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. J Immunother Cancer. 2021;9: pubmed publisher
  25. Souza C, Ketelut Carneiro N, Milanezi C, Faccioli L, Gardinassi L, Silva J. NLRC4 inhibits NLRP3 inflammasome and abrogates effective antifungal CD8+ T cell responses. iScience. 2021;24:102548 pubmed publisher
  26. Uyanik B, Goloudina A, Akbarali A, Grigorash B, Petukhov A, Singhal S, et al. Inhibition of the DNA damage response phosphatase PPM1D reprograms neutrophils to enhance anti-tumor immune responses. Nat Commun. 2021;12:3622 pubmed publisher
  27. Wang J, Zhang Y, Xiao Y, Yuan X, Li P, Wang X, et al. Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer. Am J Cancer Res. 2021;11:2005-2024 pubmed
  28. Totten S, Im Y, Cepeda Cañedo E, Najyb O, Nguyen A, Hebert S, et al. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nat Commun. 2021;12:3299 pubmed publisher
  29. Zhang H, Xia Y, Wang F, Luo M, Yang K, Liang S, et al. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression. Adv Sci (Weinh). 2021;8:2003404 pubmed publisher
  30. Lin Q, Rong L, Jia X, Li R, Yu B, Hu J, et al. IFN-γ-dependent NK cell activation is essential to metastasis suppression by engineered Salmonella. Nat Commun. 2021;12:2537 pubmed publisher
  31. Petty A, Dai R, Lapalombella R, Baiocchi R, Benson D, Li Z, et al. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function. JCI Insight. 2021;6: pubmed publisher
  32. Shen T, Liu J, Wang C, Rixiati Y, Li S, Cai L, et al. Targeting Erbin in B cells for therapy of lung metastasis of colorectal cancer. Signal Transduct Target Ther. 2021;6:115 pubmed publisher
  33. Xiao Y, Shu L, Wu X, Liu Y, Cheong L, Liao B, et al. Fatty acid binding protein 4 promotes autoimmune diabetes by recruitment and activation of pancreatic islet macrophages. JCI Insight. 2021;6: pubmed publisher
  34. Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O, et al. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A. 2021;118: pubmed publisher
  35. Turner C, Bolsoni J, Zeglinski M, Zhao H, Ponomarev T, Richardson K, et al. Granzyme B mediates impaired healing of pressure injuries in aged skin. NPJ Aging Mech Dis. 2021;7:6 pubmed publisher
  36. Liu J, Wang C, Cheng T, Rixiati Y, Ji C, Deng M, et al. Circadian Clock Disruption Suppresses PDL1+ Intraepithelial B Cells in Experimental Colitis and Colitis-Associated Colorectal Cancer. Cell Mol Gastroenterol Hepatol. 2021;12:251-276 pubmed publisher
  37. Mondal T, Shivange G, Tihagam R, Lyerly E, Battista M, Talwar D, et al. Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies. EMBO Mol Med. 2021;13:e12716 pubmed publisher
  38. Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, et al. Targeted immunotherapy for HER2-low breast cancer with 17p loss. Sci Transl Med. 2021;13: pubmed publisher
  39. Wang F, Ye W, Wang S, He Y, Zhong H, Wang Y, et al. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. Neoplasia. 2021;23:281-293 pubmed publisher
  40. Wang Y, Mohseni M, Grauel A, Diez J, Guan W, Liang S, et al. SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms. Sci Rep. 2021;11:1399 pubmed publisher
  41. Snyder M, Sembrat J, Noda K, MYERBURG M, Craig A, Mitash N, et al. Human Lung-Resident Macrophages Colocalize with and Provide Costimulation to PD1hi Tissue-Resident Memory T Cells. Am J Respir Crit Care Med. 2021;203:1230-1244 pubmed publisher
  42. Li N, Kang Y, Wang L, Huff S, Tang R, Hui H, et al. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci U S A. 2020;117:20159-20170 pubmed publisher
  43. Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Moderbacher C, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489-1501.e15 pubmed publisher
  44. Fan Z, Tian Y, Chen Z, Liu L, Zhou Q, He J, et al. Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. EMBO Mol Med. 2020;12:e11571 pubmed publisher
  45. Ruscetti M, Morris J, Mezzadra R, Russell J, Leibold J, Romesser P, et al. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. Cell. 2020;181:424-441.e21 pubmed publisher
  46. Wang J, Li P, Yu Y, Fu Y, Jiang H, Lu M, et al. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science. 2020;367: pubmed publisher
  47. Marchingo J, Sinclair L, Howden A, Cantrell D. Quantitative analysis of how Myc controls T cell proteomes and metabolic pathways during T cell activation. elife. 2020;9: pubmed publisher
  48. Terashima Y, Toda E, Itakura M, Otsuji M, Yoshinaga S, Okumura K, et al. Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties. Nat Commun. 2020;11:609 pubmed publisher
  49. Blagih J, Zani F, Chakravarty P, Hennequart M, Pilley S, Hobor S, et al. Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Rep. 2020;30:481-496.e6 pubmed publisher
  50. Wei J, Long L, Zheng W, Dhungana Y, Lim S, Guy C, et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. 2019;576:471-476 pubmed publisher
  51. Shi L, Wang J, Ding N, Zhang Y, Zhu Y, Dong S, et al. Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nat Commun. 2019;10:5421 pubmed publisher
  52. Leone R, Zhao L, Englert J, Sun I, Oh M, Sun I, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366:1013-1021 pubmed publisher
  53. Wolf Y, Bartok O, Patkar S, Eli G, Cohen S, Litchfield K, et al. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell. 2019;179:219-235.e21 pubmed publisher
  54. Di Blasi D, Boldanova T, Mori L, Terracciano L, Heim M, De Libero G. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma. Cell Mol Gastroenterol Hepatol. 2020;9:195-218 pubmed publisher
  55. Dong M, Wang G, Chow R, Ye L, Zhu L, Dai X, et al. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell. 2019;178:1189-1204.e23 pubmed publisher
  56. Leclerc M, Voilin E, Gros G, Corgnac S, de Montpreville V, Validire P, et al. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019;10:3345 pubmed publisher
  57. Meckiff B, Ladell K, McLaren J, Ryan G, Leese A, James E, et al. Primary EBV Infection Induces an Acute Wave of Activated Antigen-Specific Cytotoxic CD4+ T Cells. J Immunol. 2019;203:1276-1287 pubmed publisher
  58. Kim A, Han C, Driver I, Olow A, Sewell A, Zhang Z, et al. LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody-Induced Tumor Cell Killing by Effector CD8+ T Cells. J Immunol. 2019;203:1076-1087 pubmed publisher
  59. Miao Y, Yang H, Levorse J, Yuan S, Polak L, Sribour M, et al. Adaptive Immune Resistance Emerges from Tumor-Initiating Stem Cells. Cell. 2019;177:1172-1186.e14 pubmed publisher
  60. LaFleur M, Nguyen T, Coxe M, Yates K, Trombley J, Weiss S, et al. A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system. Nat Commun. 2019;10:1668 pubmed publisher
  61. Spolski R, West E, Li P, Veenbergen S, Yung S, Kazemian M, et al. IL-21/type I interferon interplay regulates neutrophil-dependent innate immune responses to Staphylococcus aureus. elife. 2019;8: pubmed publisher
  62. Cao Y, Trillo Tinoco J, Sierra R, Anadon C, Dai W, Mohamed E, et al. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. Nat Commun. 2019;10:1280 pubmed publisher
  63. Davies A, Kim H, González Cano R, Choi J, Back S, Roh S, et al. Natural Killer Cells Degenerate Intact Sensory Afferents following Nerve Injury. Cell. 2019;176:716-728.e18 pubmed publisher
  64. Lee Y, Ju J, Shon W, Oh S, Min C, Kang M, et al. Skewed Dendritic Cell Differentiation of MyD88-Deficient Donor Bone Marrow Cells, Instead of Massive Expansion as Myeloid-Derived Suppressor Cells, Aggravates GVHD. Immune Netw. 2018;18:e44 pubmed publisher
  65. Quandt J, Schlude C, Bartoschek M, Will R, Cid Arregui A, Schölch S, et al. Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. Oncoimmunology. 2018;7:e1500671 pubmed publisher
  66. Muscate F, Stetter N, Schramm C, Schulze zur Wiesch J, Bosurgi L, Jacobs T. HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage. Front Immunol. 2018;9:2611 pubmed publisher
  67. Wang F, Meng M, Mo B, Yang Y, Ji Y, Huang P, et al. Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function. Nat Commun. 2018;9:4874 pubmed publisher
  68. Dias J, Boulouis C, Gorin J, van den Biggelaar R, Lal K, Gibbs A, et al. The CD4-CD8- MAIT cell subpopulation is a functionally distinct subset developmentally related to the main CD8+ MAIT cell pool. Proc Natl Acad Sci U S A. 2018;115:E11513-E11522 pubmed publisher
  69. Wilgenburg B, Loh L, Chen Z, Pediongco T, Wang H, Shi M, et al. MAIT cells contribute to protection against lethal influenza infection in vivo. Nat Commun. 2018;9:4706 pubmed publisher
  70. Geary C, Krishna C, Lau C, Adams N, Gearty S, Pritykin Y, et al. Non-redundant ISGF3 Components Promote NK Cell Survival in an Auto-regulatory Manner during Viral Infection. Cell Rep. 2018;24:1949-1957.e6 pubmed publisher
  71. Tan B, Shi X, Zhang J, Qin J, Zhang N, Ren H, et al. Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization. Cancer Res. 2018;78:4929-4942 pubmed publisher
  72. Russo V, Klein T, Lim D, Solis N, Machado Y, Hiroyasu S, et al. Granzyme B is elevated in autoimmune blistering diseases and cleaves key anchoring proteins of the dermal-epidermal junction. Sci Rep. 2018;8:9690 pubmed publisher
  73. Galperin M, Farenc C, Mukhopadhyay M, Jayasinghe D, Decroos A, Benati D, et al. CD4+ T cell-mediated HLA class II cross-restriction in HIV controllers. Sci Immunol. 2018;3: pubmed publisher
  74. Anker J, Naseem A, Mok H, Schaeffer A, Abdulkadir S, Thumbikat P. Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun. 2018;9:1591 pubmed publisher
  75. Xiao F, Ai G, Yan W, Wan X, Luo X, Ning Q. Intrahepatic recruitment of cytotoxic NK cells contributes to autoimmune hepatitis progression. Cell Immunol. 2018;327:13-20 pubmed publisher
  76. Li M, Zhang W, Liu J, Li M, Zhang Y, Xiong Y, et al. Dynamic changes in the immunological characteristics of T lymphocytes in surviving patients with severe fever with thrombocytopenia syndrome (SFTS). Int J Infect Dis. 2018;70:72-80 pubmed publisher
  77. Xi J, Huang Q, Wang L, Ma X, Deng Q, Kumar M, et al. miR-21 depletion in macrophages promotes tumoricidal polarization and enhances PD-1 immunotherapy. Oncogene. 2018;37:3151-3165 pubmed publisher
  78. Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed publisher
  79. Böttcher J, Bonavita E, Chakravarty P, Blees H, Cabeza Cabrerizo M, Sammicheli S, et al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell. 2018;172:1022-1037.e14 pubmed publisher
  80. Tavazoie M, Pollack I, Tanqueco R, Ostendorf B, Reis B, Gonsalves F, et al. LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer. Cell. 2018;172:825-840.e18 pubmed publisher
  81. Pan D, Kobayashi A, Jiang P, Ferrari de Andrade L, Tay R, Luoma A, et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science. 2018;359:770-775 pubmed publisher
  82. Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira N, et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91-95 pubmed publisher
  83. Giampazolias E, Zunino B, Dhayade S, Bock F, Cloix C, Cao K, et al. Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency. Nat Cell Biol. 2017;19:1116-1129 pubmed publisher
  84. Billerbeck E, Wolfisberg R, Fahnøe U, Xiao J, Quirk C, Luna J, et al. Mouse models of acute and chronic hepacivirus infection. Science. 2017;357:204-208 pubmed publisher
  85. Domae E, Hirai Y, Ikeo T, Goda S, Shimizu Y. Cytokine-mediated activation of human ex vivo-expanded V?9V?2 T cells. Oncotarget. 2017;8:45928-45942 pubmed publisher
  86. Miao T, Symonds A, Singh R, Symonds J, Ogbe A, Omodho B, et al. Egr2 and 3 control adaptive immune responses by temporally uncoupling expansion from T cell differentiation. J Exp Med. 2017;214:1787-1808 pubmed publisher
  87. Djaoud Z, Guethlein L, Horowitz A, Azzi T, Nemat Gorgani N, Olive D, et al. Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and ?? T cells. J Exp Med. 2017;214:1827-1841 pubmed publisher
  88. Guo Q, Minnier J, Burchard J, Chiotti K, Spellman P, Schedin P. Physiologically activated mammary fibroblasts promote postpartum mammary cancer. JCI Insight. 2017;2:e89206 pubmed publisher
  89. Scott N, Rogers L, Prudova A, Brown N, Fortelny N, Overall C, et al. Interactome disassembly during apoptosis occurs independent of caspase cleavage. Mol Syst Biol. 2017;13:906 pubmed publisher
  90. Förster M, Boora R, Petrov J, Fodil N, Albanese I, Kim J, et al. A role for the histone H2A deubiquitinase MYSM1 in maintenance of CD8+ T cells. Immunology. 2017;151:110-121 pubmed publisher
  91. Li M, Bozzacco L, Hoffmann H, Breton G, Loschko J, Xiao J, et al. Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion. J Exp Med. 2016;213:2931-2947 pubmed
  92. Galindo Albarrán A, López Portales O, Gutiérrez Reyna D, Rodríguez Jorge O, Sánchez Villanueva J, Ramirez Pliego O, et al. CD8+ T Cells from Human Neonates Are Biased toward an Innate Immune Response. Cell Rep. 2016;17:2151-2160 pubmed publisher
  93. Srivastava R, Khan A, Garg S, Syed S, Furness J, Vahed H, et al. Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocula. J Virol. 2017;91: pubmed publisher
  94. Cuff A, Robertson F, Stegmann K, Pallett L, Maini M, Davidson B, et al. Eomeshi NK Cells in Human Liver Are Long-Lived and Do Not Recirculate but Can Be Replenished from the Circulation. J Immunol. 2016;197:4283-4291 pubmed
  95. Starobinets H, Ye J, Broz M, Barry K, Goldsmith J, Marsh T, et al. Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment. J Clin Invest. 2016;126:4417-4429 pubmed publisher
  96. Klotz L, Kuzmanov I, Hucke S, Gross C, Posevitz V, Dreykluft A, et al. B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. Proc Natl Acad Sci U S A. 2016;113:E6182-E6191 pubmed
  97. Bernard Valnet R, Yshii L, Quériault C, Nguyen X, Arthaud S, Rodrigues M, et al. CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. Proc Natl Acad Sci U S A. 2016;113:10956-61 pubmed publisher
  98. Pachnio A, Ciáurriz M, Begum J, Lal N, Zuo J, Beggs A, et al. Cytomegalovirus Infection Leads to Development of High Frequencies of Cytotoxic Virus-Specific CD4+ T Cells Targeted to Vascular Endothelium. PLoS Pathog. 2016;12:e1005832 pubmed publisher
  99. Leong Y, Chen Y, Ong H, Wu D, Man K, Deléage C, et al. CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles. Nat Immunol. 2016;17:1187-96 pubmed publisher
  100. Nakhlé J, Pierron V, Bauchet A, Plas P, Thiongane A, Meyer Losic F, et al. Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer. Oncoimmunology. 2016;5:e1145333 pubmed publisher
  101. Wang Y, Sun H, Wang J, Wang H, Meng L, Xu C, et al. DNA-PK-mediated phosphorylation of EZH2 regulates the DNA damage-induced apoptosis to maintain T-cell genomic integrity. Cell Death Dis. 2016;7:e2316 pubmed publisher
  102. Cao G, Wang Q, Li G, Meng Z, Liu H, Tong J, et al. mTOR inhibition potentiates cytotoxicity of V?4 ?? T cells via up-regulating NKG2D and TNF-?. J Leukoc Biol. 2016;100:1181-1189 pubmed
  103. Lee Chang C, Bodogai M, Moritoh K, Chen X, Wersto R, Sen R, et al. Aging Converts Innate B1a Cells into Potent CD8+ T Cell Inducers. J Immunol. 2016;196:3385-97 pubmed publisher
  104. Bulla R, Tripodo C, Rami D, Ling G, Agostinis C, Guarnotta C, et al. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun. 2016;7:10346 pubmed publisher
  105. Roan F, Stoklasek T, Whalen E, Molitor J, Bluestone J, Buckner J, et al. CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis. J Immunol. 2016;196:2051-2062 pubmed publisher
  106. Mangan M, Bird C, Kaiserman D, Matthews A, Hitchen C, Steer D, et al. A Novel Serpin Regulatory Mechanism: SerpinB9 IS REVERSIBLY INHIBITED BY VICINAL DISULFIDE BOND FORMATION IN THE REACTIVE CENTER LOOP. J Biol Chem. 2016;291:3626-38 pubmed publisher
  107. Pearce V, Bouabe H, MacQueen A, Carbonaro V, Okkenhaug K. PI3Kδ Regulates the Magnitude of CD8+ T Cell Responses after Challenge with Listeria monocytogenes. J Immunol. 2015;195:3206-17 pubmed publisher
  108. Leeansyah E, Svärd J, Dias J, Buggert M, Nyström J, Quigley M, et al. Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7 and Defective in HIV-1 Infection. PLoS Pathog. 2015;11:e1005072 pubmed publisher
  109. Marshall M, Pattu V, Halimani M, Maier Peuschel M, Müller M, Becherer U, et al. VAMP8-dependent fusion of recycling endosomes with the plasma membrane facilitates T lymphocyte cytotoxicity. J Cell Biol. 2015;210:135-51 pubmed publisher
  110. Mikucki M, Fisher D, Matsuzaki J, Skitzki J, Gaulin N, Muhitch J, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun. 2015;6:7458 pubmed publisher
  111. Becker P, Hervouet C, Mason G, KWON S, Klavinskis L. Skin vaccination with live virus vectored microneedle arrays induce long lived CD8(+) T cell memory. Vaccine. 2015;33:4691-8 pubmed publisher
  112. Sharma S, Chintala N, Vadrevu S, Patel J, Karbowniczek M, Markiewski M. Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs. J Immunol. 2015;194:5529-38 pubmed publisher
  113. Rao E, Zhang Y, Zhu G, Hao J, Persson X, Egilmez N, et al. Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death. Oncotarget. 2015;6:7944-58 pubmed
  114. Srivastava R, Khan A, Spencer D, Vahed H, Lopes P, Thai N, et al. HLA-A02:01-restricted epitopes identified from the herpes simplex virus tegument protein VP11/12 preferentially recall polyfunctional effector memory CD8+ T cells from seropositive asymptomatic individuals and protect humanized HLA-A*02:01 transgenic. J Immunol. 2015;194:2232-48 pubmed publisher
  115. Khan A, Srivastava R, Spencer D, Garg S, Fremgen D, Vahed H, et al. Phenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpes. J Virol. 2015;89:3776-92 pubmed publisher
  116. Zhang P, Lu X, Tao K, Shi L, Li W, Wang G, et al. Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma. J Surg Res. 2015;194:107-13 pubmed publisher
  117. Kobayashi T, Hamaguchi Y, Hasegawa M, Fujimoto M, Takehara K, Matsushita T. B cells promote tumor immunity against B16F10 melanoma. Am J Pathol. 2014;184:3120-9 pubmed publisher
  118. Baker G, Chockley P, Yadav V, Doherty R, Ritt M, Sivaramakrishnan S, et al. Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res. 2014;74:5079-90 pubmed publisher
  119. Adoro S, McCaughtry T, Erman B, Alag A, Van Laethem F, Park J, et al. Coreceptor gene imprinting governs thymocyte lineage fate. EMBO J. 2012;31:366-77 pubmed publisher
  120. Lin P, Sun L, Thibodeaux S, Ludwig S, Vadlamudi R, Hurez V, et al. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol. 2010;185:2747-53 pubmed publisher
  121. Waugh C, Sinclair L, Finlay D, Bayascas J, Cantrell D. Phosphoinositide (3,4,5)-triphosphate binding to phosphoinositide-dependent kinase 1 regulates a protein kinase B/Akt signaling threshold that dictates T-cell migration, not proliferation. Mol Cell Biol. 2009;29:5952-62 pubmed publisher
  122. Ahonen C, Wasiuk A, Fuse S, Turk M, Ernstoff M, Suriawinata A, et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood. 2008;111:3116-25 pubmed publisher
  123. Hickman H, Takeda K, Skon C, Murray F, Hensley S, Loomis J, et al. Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes. Nat Immunol. 2008;9:155-65 pubmed publisher